Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours

Reuters10-20

Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours

Iksuda Therapeutics, a portfolio company of IP Group plc, has announced the presentation of new data from its Phase 1 clinical study of IKS014, a HER2-directed antibody-drug conjugate, at the European Society for Medical Oncology (ESMO) Congress in Berlin. The ongoing trial is evaluating IKS014 in patients with advanced HER2-positive solid tumours. As of July 31, 2025, 62 patients had been enrolled, with 55 evaluable for efficacy. Anti-tumour activity was observed across all dose levels in multiple tumour types, including breast, lung, oesophageal, ovarian, gastric, gallbladder, and gastroesophageal junction cancers, as well as both HER2-positive and HER2-low tumours. The maximum tolerated dose was not reached, and dose selection for further evaluation will be based on preliminary activity, safety, pharmacokinetics, pharmacodynamics, and overall benefit-risk assessment. The Phase 1 trial is expected to complete in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576855789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576855789","market":"fut","top_or_hot":-1,"title":"Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iksuda <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a portfolio company of IP Group plc, has announced the presentation of new data from its Phase 1 clinical study of IKS014, a HER2-directed antibody-drug conjugate, at the European Society for Medical Oncology (ESMO) Congress in Berlin. The ongoing trial is evaluating IKS014 in patients with advanced HER2-positive solid tumours. As of July 31, 2025, 62 patients had been enrolled, with 55 evaluable for efficacy. Anti-tumour activity was observed across all dose levels in multiple tumour types, including breast, lung, oesophageal, ovarian, gastric, gallbladder, and gastroesophageal junction cancers, as well as both HER2-positive and HER2-low tumours. The maximum tolerated dose was not reached, and dose selection for further evaluation will be based on preliminary activity, safety, pharmacokinetics, pharmacodynamics, and overall benefit-risk assessment. The Phase 1 trial is expected to complete in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iksuda <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a portfolio company of IP Group plc, has announced the presentation of new data from its Phase 1 clinical study of IKS014, a HER2-directed antibody-drug conjugate, at the European Society for Medical Oncology (ESMO) Congress in Berlin. The ongoing trial is evaluating IKS014 in patients with advanced HER2-positive solid tumours. As of July 31, 2025, 62 patients had been enrolled, with 55 evaluable for efficacy. Anti-tumour activity was observed across all dose levels in multiple tumour types, including breast, lung, oesophageal, ovarian, gastric, gallbladder, and gastroesophageal junction cancers, as well as both HER2-positive and HER2-low tumours. The maximum tolerated dose was not reached, and dose selection for further evaluation will be based on preliminary activity, safety, pharmacokinetics, pharmacodynamics, and overall benefit-risk assessment. The Phase 1 trial is expected to complete in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL3Q1S8k:1","article_id":"2576855789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576855789","pubTimestamp":1760959424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Iksuda Therapeutics, a portfolio company of IP Group plc, has announced the presentation of new data from its Phase 1 clinical study of IKS014, a HER2-directed antibody-drug conjugate, at the European Society for Medical Oncology  Congress in Berlin. The ongoing trial is evaluating IKS014 in patients with advanced HER2-positive solid tumours. As of July 31, 2025, 62 patients had been enrolled, with 55 evaluable for efficacy. Anti-tumour activity was observed across all dose levels in multiple tumour types, including breast, lung, oesophageal, ovarian, gastric, gallbladder, and gastroesophageal junction cancers, as well as both HER2-positive and HER2-low tumours. The maximum tolerated dose was not reached, and dose selection for further evaluation will be based on preliminary activity, safety, pharmacokinetics, pharmacodynamics, and overall benefit-risk assessment. The Phase 1 trial is expected to complete in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"Iksuda报告IKS014在晚期HER2+肿瘤中的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"Iksuda Reports Positive Phase 1 Results for IKS014 in Advanced HER2+ Tumours\n    \n\n        Iksuda Therapeutics, a portfolio company of IP Group plc, has announced the presentation of new data from its Phase 1 clinical study of IKS014, a HER2-directed antibody-drug conjugate, at the European Society for Medical Oncology (ESMO) Congress in Berlin. The ongoing trial is evaluating IKS014 in patients with advanced HER2-positive solid tumours. As of July 31, 2025, 62 patients had been enrolled, with 55 evaluable for efficacy. Anti-tumour activity was observed across all dose levels in multiple tumour types, including breast, lung, oesophageal, ovarian, gastric, gallbladder, and gastroesophageal junction cancers, as well as both HER2-positive and HER2-low tumours. The maximum tolerated dose was not reached, and dose selection for further evaluation will be based on preliminary activity, safety, pharmacokinetics, pharmacodynamics, and overall benefit-risk assessment. The Phase 1 trial is expected to complete in the second half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576855789","isCrawlerRequest":true}